Cargando…
Impact of Fixed Combination of Metformin and Pioglitazone on Insulin Resistance of Patients with Type 2 Diabetes: Results of a Randomized Open-Label Study
AIM: To compare the effect of metformin, a fixed combination of metformin and pioglitazone, or dapagliflozin on insulin resistance in patients with newly diagnosed type 2 diabetes. METHODS: In this 6-week randomized open-label trial, 58 patients were randomly assigned to insulin with metformin, a fi...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10518260/ https://www.ncbi.nlm.nih.gov/pubmed/37753480 http://dx.doi.org/10.2147/DMSO.S423322 |
_version_ | 1785109473708212224 |
---|---|
author | Sun, Rui Yuan, Lu Shen, Yun Shen, Ziyang Ding, Bo Ma, Jianhua |
author_facet | Sun, Rui Yuan, Lu Shen, Yun Shen, Ziyang Ding, Bo Ma, Jianhua |
author_sort | Sun, Rui |
collection | PubMed |
description | AIM: To compare the effect of metformin, a fixed combination of metformin and pioglitazone, or dapagliflozin on insulin resistance in patients with newly diagnosed type 2 diabetes. METHODS: In this 6-week randomized open-label trial, 58 patients were randomly assigned to insulin with metformin, a fixed combination of metformin and pioglitazone, or dapagliflozin for 4 weeks. Hyperinsulinemic euglycemic clamp tests and FreeStyle Libre Pro Sensor were used to evaluate the insulin sensitivity represented by glucose-infusion rate (M value) and glycemic control, respectively. The main outcome was changes in insulin resistance compared with baseline. RESULTS: The baseline characteristics were well matched among the three groups. When compared to baseline, insulin sensitivity after treatment was significantly improved. Further study revealed that the fixed combination of metformin and pioglitazone provided superior M-value improvement compared with metformin, but not different from dapagliflozin. Moreover, a greater reduction in insulin dose was observed in the fixed combination of metformin and pioglitazone group than the metformin or dapagliflozin group. However, there were no significant differences in the parameters of glycemic control within the groups. CONCLUSION: In patients with newly diagnosed type 2 diabetes, a fixed combination of metformin and pioglitazone provided greater improvement in insulin resistance than metformin alone and similar changes in insulin resistance to dapagliflozin. |
format | Online Article Text |
id | pubmed-10518260 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-105182602023-09-26 Impact of Fixed Combination of Metformin and Pioglitazone on Insulin Resistance of Patients with Type 2 Diabetes: Results of a Randomized Open-Label Study Sun, Rui Yuan, Lu Shen, Yun Shen, Ziyang Ding, Bo Ma, Jianhua Diabetes Metab Syndr Obes Clinical Trial Report AIM: To compare the effect of metformin, a fixed combination of metformin and pioglitazone, or dapagliflozin on insulin resistance in patients with newly diagnosed type 2 diabetes. METHODS: In this 6-week randomized open-label trial, 58 patients were randomly assigned to insulin with metformin, a fixed combination of metformin and pioglitazone, or dapagliflozin for 4 weeks. Hyperinsulinemic euglycemic clamp tests and FreeStyle Libre Pro Sensor were used to evaluate the insulin sensitivity represented by glucose-infusion rate (M value) and glycemic control, respectively. The main outcome was changes in insulin resistance compared with baseline. RESULTS: The baseline characteristics were well matched among the three groups. When compared to baseline, insulin sensitivity after treatment was significantly improved. Further study revealed that the fixed combination of metformin and pioglitazone provided superior M-value improvement compared with metformin, but not different from dapagliflozin. Moreover, a greater reduction in insulin dose was observed in the fixed combination of metformin and pioglitazone group than the metformin or dapagliflozin group. However, there were no significant differences in the parameters of glycemic control within the groups. CONCLUSION: In patients with newly diagnosed type 2 diabetes, a fixed combination of metformin and pioglitazone provided greater improvement in insulin resistance than metformin alone and similar changes in insulin resistance to dapagliflozin. Dove 2023-09-20 /pmc/articles/PMC10518260/ /pubmed/37753480 http://dx.doi.org/10.2147/DMSO.S423322 Text en © 2023 Sun et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Clinical Trial Report Sun, Rui Yuan, Lu Shen, Yun Shen, Ziyang Ding, Bo Ma, Jianhua Impact of Fixed Combination of Metformin and Pioglitazone on Insulin Resistance of Patients with Type 2 Diabetes: Results of a Randomized Open-Label Study |
title | Impact of Fixed Combination of Metformin and Pioglitazone on Insulin Resistance of Patients with Type 2 Diabetes: Results of a Randomized Open-Label Study |
title_full | Impact of Fixed Combination of Metformin and Pioglitazone on Insulin Resistance of Patients with Type 2 Diabetes: Results of a Randomized Open-Label Study |
title_fullStr | Impact of Fixed Combination of Metformin and Pioglitazone on Insulin Resistance of Patients with Type 2 Diabetes: Results of a Randomized Open-Label Study |
title_full_unstemmed | Impact of Fixed Combination of Metformin and Pioglitazone on Insulin Resistance of Patients with Type 2 Diabetes: Results of a Randomized Open-Label Study |
title_short | Impact of Fixed Combination of Metformin and Pioglitazone on Insulin Resistance of Patients with Type 2 Diabetes: Results of a Randomized Open-Label Study |
title_sort | impact of fixed combination of metformin and pioglitazone on insulin resistance of patients with type 2 diabetes: results of a randomized open-label study |
topic | Clinical Trial Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10518260/ https://www.ncbi.nlm.nih.gov/pubmed/37753480 http://dx.doi.org/10.2147/DMSO.S423322 |
work_keys_str_mv | AT sunrui impactoffixedcombinationofmetforminandpioglitazoneoninsulinresistanceofpatientswithtype2diabetesresultsofarandomizedopenlabelstudy AT yuanlu impactoffixedcombinationofmetforminandpioglitazoneoninsulinresistanceofpatientswithtype2diabetesresultsofarandomizedopenlabelstudy AT shenyun impactoffixedcombinationofmetforminandpioglitazoneoninsulinresistanceofpatientswithtype2diabetesresultsofarandomizedopenlabelstudy AT shenziyang impactoffixedcombinationofmetforminandpioglitazoneoninsulinresistanceofpatientswithtype2diabetesresultsofarandomizedopenlabelstudy AT dingbo impactoffixedcombinationofmetforminandpioglitazoneoninsulinresistanceofpatientswithtype2diabetesresultsofarandomizedopenlabelstudy AT majianhua impactoffixedcombinationofmetforminandpioglitazoneoninsulinresistanceofpatientswithtype2diabetesresultsofarandomizedopenlabelstudy |